Last reviewed · How we verify
Dexchlorpheniramine 1% lotion
Dexchlorpheniramine is a first-generation H1-receptor antagonist that blocks histamine binding to reduce allergic and inflammatory responses in the skin.
Dexchlorpheniramine is a first-generation H1-receptor antagonist that blocks histamine binding to reduce allergic and inflammatory responses in the skin. Used for Pruritus and allergic dermatitis (topical treatment), Urticaria and other allergic skin conditions.
At a glance
| Generic name | Dexchlorpheniramine 1% lotion |
|---|---|
| Sponsor | Mantecorp Industria Quimica e Farmaceutica Ltd. |
| Drug class | H1-receptor antagonist (first-generation antihistamine) |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Allergy |
| Phase | Phase 3 |
Mechanism of action
As a potent H1-receptor antagonist, dexchlorpheniramine competitively inhibits histamine at H1 receptors on mast cells, endothelial cells, and other tissues, thereby reducing itching, erythema, and other allergic manifestations. The lotion formulation allows topical delivery to affected skin areas, providing localized antihistamine and anti-inflammatory effects with reduced systemic absorption compared to oral formulations.
Approved indications
- Pruritus and allergic dermatitis (topical treatment)
- Urticaria and other allergic skin conditions
Common side effects
- Local skin irritation
- Contact dermatitis
- Drowsiness (if systemically absorbed)
Key clinical trials
- Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Sunburn Related Symptoms (PHASE3)
- Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Insect Bite Related Symptoms (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: